Nodules after a biostimulator: types and management

Yes, a biostimulator can cause a nodule, and knowing what kind of nodule you are dealing with is what defines management. Unlike a nodule from hyaluronic acid, which can be broken down with hyaluronidase, a nodule from a collagen biostimulator has no enzymatic reversal. That makes prevention, diagnosis and record keeping even more important.

This guide is a review. It gives no doses, dilutions or treatment protocols: management is defined by the qualified professional, according to the case and the rules of their professional council, often together with other specialties. The general overview of complications is in safety and complications.

What are the types of nodule after a biostimulator?

The most useful way to classify them is to cross time of onset with the presence of inflammation.

The division between early and late is not rigid. What most separates the pictures, in practice, is the presence of inflammatory signs and the distribution pattern.

Why does the nodule appear?

In most cases, an early biostimulator nodule has a technical or indication-related explanation:

• Product too superficial, in thin skin, where any buildup becomes palpable or visible.
• A highly mobile area, such as the lips and the periorbital area, where the muscles concentrate the product. These areas are usually avoided with biostimulators.
• Concentration at a single point, when the product was meant for diffuse stimulation.
• Preparation that departs from what the manufacturer describes, for reconstituted products such as poly-L-lactic acid.
• Expectation of immediate volume leading to a larger amount than needed.

The late inflammatory nodule, on the other hand, has a less predictable origin. Granulomatous foreign body reaction and biofilm can appear in patients with no prior problem, sometimes after a trigger such as an infection, a vaccine or another procedure on the face. The differences in behavior between the two most used classes are in calcium hydroxylapatite vs poly-L-lactic acid.

How do you investigate a nodule after a biostimulator?

The investigation starts with the patient record. Without knowing which product, lot, area, date and amount were used, the diagnosis becomes a guess. If the injection was done by another professional, ask the patient for these details.

Points that usually enter the assessment:

1. Time since the injection and whether the nodule appeared all at once or grew gradually.
2. Inflammatory signs: pain, warmth, redness, surrounding hardening, fluctuance.
3. Distribution: a single point, several points treated at the same time, or also in areas treated with other products.
4. Recent triggers: infection, dental procedure, vaccine, another injectable.
5. Filler history, including permanent products injected years earlier, which the patient sometimes forgets to mention.

Soft-tissue ultrasound is often cited for locating the material, estimating the plane it is in and telling product, fluid collection and other structures apart. Calcium hydroxylapatite is also radiopaque and can show up on X-rays and CT scans. In late and recurrent pictures, a biopsy may be needed to confirm a granuloma or rule out other causes.

What management approaches are described, at review level?

Management depends on the type of nodule, the product and the clinical picture. In general terms, the literature describes:

• Observation and reassessment for early diffuse hardening, which often shrinks as the swelling resolves.
• Mechanical and local approaches for noninflammatory nodules, aiming to disperse the material, depending on the product and the assessment.
• Treatment of infection when there are compatible signs, with an antibiotic according to assessment and, when indicated, drainage.
• Anti-inflammatory medications for confirmed granulomatous reactions, generally after infection or biofilm has been ruled out.
• Specific approaches under study, such as agents described in reports and case series for calcium hydroxylapatite nodules, still without consensus.
• Surgical removal in selected cases, persistent or with a significant functional or aesthetic impact.

Hyaluronidase does not act on the biostimulator. It only comes in when there is hyaluronic acid in the same area or when the injected product combines hyaluronic acid with another substance, which reinforces the importance of knowing exactly what was used.

How do you reduce the risk of nodules?

Most prevention happens before the needle or cannula:

• The right indication. Biostimulator for stimulation and firmness; immediate localized volume usually calls for another tool. The reasoning is in the overview of biostimulators.
• An area compatible with the instructions for use. Thin skin and highly mobile areas are usually left out.
• Preparation according to the manufacturer. No improvising reconstitution or mixing.
• Appropriate plane and distribution. The choice between cannula or needle is part of this decision.
• Careful medical history. Autoimmune disease, tendency to keloids, history of nodules and previous fillers. See medical history in HOF.
• Antisepsis and clean technique, to reduce the risk of infection and biofilm.
• Clear post-procedure instructions, including the care the manufacturer recommends.

How do you talk to the patient about nodules?

A patient with a nodule often arrives anxious, sometimes after searching and finding serious cases. Two things help: explaining that there are different types and showing that there is an assessment plan.

Before the injection, the risk of a nodule, including a late one, should be in the informed consent, along with the fact that the product cannot be reversed with an enzyme. A starting point is in the informed consent template for biostimulators. If the patient's concern is swelling in the first days, and not a nodule, see does a biostimulator swell the face?.

And in Harmy?

Harmy does not simulate complications: the projection shows only the volume effect of the marked areas, without skin retouching, and it is an illustrative simulation, not a promise of results. Where it helps is documentation. History keeps each patient's sessions with date and photos, and "Add actual result" stores the follow-up photo aligned by the eyes, which complements the patient record when the course needs to be reconstructed. See history and actual result.

Checklist when facing a nodule after a biostimulator

1. Product, lot, area, date and amount retrieved from the patient record.
2. Inflammatory signs assessed; infection ruled out or treated.
3. Standardized photos of the nodule at the first visit.
4. Imaging considered to locate the material.
5. Patient informed about warning signs and follow-up.
6. Management and progress recorded at each visit.
7. Referral or joint management in late or recurrent pictures.